Join to View Full Profile
55 Fruit StGrj 904Boston, MA 02114
Phone+1 617-724-1399
Fax+1 617-726-8623
Dr. Ellisen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
Stanford University School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1994 - 2025
Publications & Presentations
PubMed
- 1 citationsTOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden
Clinical Cancer Research. 2025-05-15 - 1 citationsCREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.Ki-Fong Man, Omeed Darweesh, Jinghui Hong, Alexandra Thompson, Charlotte O'Connor
Oncogene. 2025-05-01 - Correction: CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.Ki-Fong Man, Omeed Darweesh, Jinghui Hong, Alexandra Thompson, Charlotte O'Connor
Oncogene. 2025-05-01
Press Mentions
Mechanisms of Resistance to Drug for Triple-Negative Breast Cancer IdentifiedAugust 17th, 2021- Researchers Identify Mechanisms of Resistance to Drug for Triple-Negative Breast CancerAugust 17th, 2021
- Scientists Discover How Triple-Negative Breast Cancer Can Defeat Powerful DrugsAugust 16th, 2021
- Join now to see all
Grant Support
- Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancerMASSACHUSETTS GENERAL HOSPITAL2024–2029
- Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancerMASSACHUSETTS GENERAL HOSPITAL2024–2029
- Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancerMASSACHUSETTS GENERAL HOSPITAL2024–2029
- Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African AmericansMASSACHUSETTS GENERAL HOSPITAL2022–2027
- Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2022–2026
- Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2022–2026
- Landscape and characterization of promoter mutations driving triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2023–2025
- Landscape and characterization of promoter mutations driving triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2023–2025
- Landscape and characterization of promoter mutations driving triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2023–2025
- P63 Mechanisms And Mediators In HnsccNational Institute Of Dental &Craniofacial Research2011
- Function And Mechanism Of REDD1 Signaling To TSC1/2 And MTORC1National Cancer Institute2007–2011
- P63 Mediators As Therapeutic Targets In HnsccNational Institute Of Dental &Craniofacial Research2004–2010
- Telomerase Functions In Differentiation &TransformationNational Cancer Institute1999–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
